SynCore Biotechnology Co

SynCore Biotechnology Co Deferred Tax Liabilities

Deferred Tax Liabilities of SynCore Biotechnology Co (4192.TWO) as of Nov 17, 2026.

Deferred Tax Liabilities

-TWD

Last updated:

Deferred Tax Liabilities of SynCore Biotechnology Co is 2026 - TWD. Deferred Tax Liabilities of SynCore Biotechnology Co was 2025 - TWD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SynCore Biotechnology Co Stock analysis

What does SynCore Biotechnology Co do? SynCore Biotechnology Co Ltd, based in Dongshan, Yilan, Taiwan, operates in the Health Care sector with a focus on Pharmaceuticals. The company develops new drugs and integrates technology, employing 50 full-time staff. Its main product is SB03 Veregen, alongside research and development of anticancer drugs SB01 (injection and oral forms). SynCore primarily distributes its products within Taiwan. SynCore Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SynCore Biotechnology Co stock

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities SynCore Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's SynCore Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — SynCore Biotechnology Co

All Key Metrics — SynCore Biotechnology Co